EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

被引：0

作者：

Noh, H. ^{[1
]}

Choi, S. -Y. ^{[2
]}

Song, H. -Y. ^{[2
]}

Kim, S. -H. ^{[2
]}

Jung, S. Y. ^{[3
,4
]}

Yang, S. ^{[1
]}

Lee, W. -S. ^{[5
]}

Kim, H. -J. ^{[6
]}

Kong, J. H. ^{[7
]}

Kim, H. ^{[8
]}

Do, Y. R. ^{[9
]}

Kwak, J. -Y. ^{[10
]}

Oh, S. ^{[11
]}

Kim, S. H. ^{[12
]}

Kim, J. -A. ^{[13
]}

Zang, D. Y. ^{[14
]}

Mun, Y. -C. ^{[15
]}

Won, Y. -W. ^{[16
]}

Lee, S. -E. ^{[17
]}

Kim, D. -W. ^{[17
]}

Lee, J. ^{[3
,4
]}

机构：

[1] Yonsei Univ, Dept Pharm, Coll Pharm, Incheon, South Korea

[2] Catholic Univ Korea, Leukemia Res Inst, Seoul, South Korea

[3] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul, South Korea

[4] Seoul Natl Univ, Coll Pharm, Dept Pharm, Seoul, South Korea

[5] Inje Univ, Busan Paik Hosp, Coll Med, Dept Internal Med, Busan, South Korea

[6] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Hwasun, South Korea

[7] Yonsei Univ, Wonju Coll Med, Dept Hematol Oncol, Wonju, South Korea

[8] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Hematol, Ulsan, South Korea

[9] Keimyung Univ, Keimyung Univ Hosp, Sch Med, Div Hematol Oncol, Daegu, South Korea

[10] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Sch Med, Div Hematol Oncol, Jeonju, South Korea

[11] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Internal Med,Div Hematol Onco, Seoul, South Korea

[12] Dong A Univ, Dong A Univ Hosp, Coll Med, Dept Internal Med, Busan, South Korea

[13] Catholic Univ Korea, St Vincents Hosp, Dept Hematol, Suwon, South Korea

[14] Hallym Univ, Hallym Univ Hosp, Coll Med, Dept Internal Med, Anyang, South Korea

[15] Ewha Womans Univ, Ehwa Womans Univ Hosp, Sch Med, Dept Hematol, Seoul, South Korea

[16] Hanyang Univ, Guri Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med, Guri, South Korea

[17] Catholic Univ Korea, Seoul St Marys Hosp, Leukemia Res Inst, Dept Hematol, Seoul, South Korea

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P259

引用

页码：76 / 76

页数：1

共 50 条

[1] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
Cuellar, Sandra
Vozniak, Michael
Rhodes, Jill
Forcello, Nicholas
Olszta, Daniel
[J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
[2] Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Malik, Sara
Hassan, Shahzeb
Eskazan, Ahmet Emre
[J]. EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (11) : 975 - 978
[3] BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Press, Richard D.
Kamel-Reid, Suzanne
Ang, Daphne
[J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 565 - 576
[4] MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH BCR-ABL1(+) CHRONIC MYELOID LEUKEMIA PRESENTING WITH AN ISOLATED THROMBOCYTOSIS AT THE ONSET
Balatzenko, G.
Hrischev, V.
Ignatova, K.
Stoyanova, Z.
Lilova, A.
Angelova, S.
Ivanova, S.
Romanova, M.
Ivanova, I.
Tsvetkova, G.
Hadjiev, E.
Madzharova, V.
Dikov, T.
Spassov, B.
Davidkova, Y.
Jagurinoski, M.
Guenova, M.
[J]. HAEMATOLOGICA, 2017, 102 : 733 - 733
[5] Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
Haddad, Fadi
Kantarjian, Hagop
Issa, Ghayas C.
Jabbour, Elias
Sasaki, Koji
[J]. LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1714 - 1717
[6] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors
Kihel, I.
Nachi, M.
Cayuela, J.
Bekadja, M. A.
Note, A.
[J]. CLINICA CHIMICA ACTA, 2024, 558
[7] Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
Erbilgin, Yucel
Eskazan, Ahmet Emre
Ng, Ozden Hatirnaz
Salihoglu, Ayse
Elverdi, Tugrul
Firtina, Sinem
Tasar, Orcun
Mercan, Sevcan
Sisko, Sinem
Khodzhaev, Khusan
Ongoren, Seniz
Ar, Muhlis Cem
Baslar, Zafer
Soysal, Teoman
Sayitoglu, Muge
Ozbek, Ugur
[J]. LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 200 - 207
[8] Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
Sasaki, Koji
Kantarjian, Hagop
O'Brien, Susan
Ravandi, Farhad
Konopleva, Marina
Borthakur, Gautam
Garcia-Manero, Guillermo
Wierda, William
Daver, Naval
Ferrajoli, Alessandra
Takahashi, Koichi
Jain, Preetesh
Rios, Mary Beth
Pierce, Sherry
Jabbour, Elias
Cortes, Jorge E.
[J]. CANCER, 2018, 124 (06) : 1160 - 1168
[9] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
Kim, Sung-Hyun
Menon, Hari
Jootar, Saengsuree
Saikia, Tapan
Kwak, Jae-Yong
Sohn, Sang-Kyun
Park, Joon Seong
Jeong, Seong Hyun
Kim, Hyeoung Joon
Kim, Yeo-Kyeoung
Oh, Suk Joong
Kim, Hawk
Zang, Dae Young
Chung, Joo Seop
Shin, Ho Jin
Do, Young Rok
Kim, Jeong-A
Kim, Dae-Young
Choi, Chul Won
Park, Sahee
Park, Hye Lin
Lee, Gong Yeal
Cho, Dae Jin
Shin, Jae Soo
Kim, Dong-Wook
[J]. HAEMATOLOGICA, 2014, 99 (07) : 1191 - 1196
[10] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
Takeuchi, Asako
Kondo, Toshinori
Tasaka, Taizo
Yamada, Seiko
Hirose, Tadashi
Fukuda, Hirofumi
Shimizu, Risa
Matsuhashi, Yoshiko
Kondo, Eisei
Wada, Hideho
[J]. LEUKEMIA RESEARCH REPORTS, 2021, 15

← 1 2 3 4 5 →